NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for NCI-H1975 Cells (Lung Adenocarcinoma Cells, CRL-5908)
- Proprietary cationic lipids formulation
- High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
- Effective and robust intracellular delivery
- A proven reagent for establishing stable cell lines
- Download PowerPoint presentation for NCI-H1975 cells transfection kit: [PPT]
- Download NCI-H1975 CRISPR/Cas9 transfection protocol: [PDF]
- Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 94% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems NCI-H1975 Transfection Protocol: [PDF]
Download MSDS: [PDF]
NCI-H1975 Cell Line:
Although lung cancer therapeutics have evolved dramatically within last two decades, lung cancer is considered the primary cause of cancer deaths globally in both men and women. Non-small-cell lung cancers comprise approximately 80% of all lung cancer incidences and include adenocarcinomas, squamous cell carcinomas as well as large cell carcinomas. Non-small cell lung cancer is frequently diagnosed at advanced stages, with the average 5-year survival rate of only 16%. New approaches in lung cancer therapy are crucial in treating advanced-stage patients. The NCI-H1975 epithelial cell line was isolated in 1988 from lung cells taken from a non-smoker female with adenocarcinoma. NCI-H1975 is useful in investigative and analytical studies of new lung cancer drugs. Altogen Biosystems provides high-efficiency transfection reagent kits for the NCI-H1975 cell line.
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the NCI-H1975 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).
Figure 2. Protein expression of Cyclophilin B in NCI-H1975 cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into NCI-H1975 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides preoptimized transfection products for life science research applications. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, RNA, and any other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6854)
- 1.5 ml (Catalog #6855)
- 1.5 ml CRISPR (Catalog #2177)
- 8.0 ml (Catalog #7067)